Its dividend yield isn't huge. But the payout is backed by a business model built for steady growth, and the company is also ...
An experimental Alzheimer's disease drug from Eisai (4523.T) and Biogen (BIIB.O) slowed cognitive decline in a closely watched trial but may carry a risk of dangerous side effects for certain patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback